NSE filing, NSE: SUVEN. Summary written from the filing by ALFA Finder's alert engine.
Suven Life Sciences Ltd: key numbers
- Share price
- ₹258.85
- Market cap
- ₹7,314 Cr
- Revenue (annual)
- ₹7.11 Cr
- Net profit (annual)
- ₹-276.3 Cr
- P/E (TTM)
- -20.8×Sector 52.8×
- Promoter holding
- 65.47%-4.61% QoQ
- FII holding
- 0.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suven Life Sciences Ltd
All →Suven Life Sciences Board Meeting Date
Suven Life Sciences scheduled its board meeting for 5 November 2026 to approve Q1 and H1 FY27 unaudited results. The trading window closed from 1 October 2026 until 48 hours post-declaration.
Suven Life Sciences Other Announcement
Suven Life Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, pursuant to SEBI regulations.
Suven Life Sciences Business Update
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
- clinical trial enrollment
- 424.0 patients
Suven Life Sciences Annual General Meeting
Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026. The company submitted the proceedings, scrutineer's report, and voting results.
Suven Life Sciences Other Announcement
Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.
- Value
- ₹857.6 Cr
Suven Life Sciences Q1 FY27 Results: Net Loss of ₹127.6 Cr, Loss Widens
Suven Life Sciences Ltd reported revenue from operations of ₹3.6 Cr (+89.5% YoY) and a net loss of ₹127.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹127.6 Cr
Other management change announcements
All →NHPC Management Change
NHPC disclosed that Executive Director Shri Vivek Dwivedi's tenure ends on superannuation, effective October 31, 2026. The filing reports no replacement or financial impact.
BEML Management Change
BEML Limited informed exchanges that two senior executives, including the Executive Director (Offg.) Aparup Sinha, ceased office on superannuation effective 31 October 2026. No monetary value is involved.
Jay Jalaram Technologies Management Change
Jay Jalaram Technologies appointed Varjivandas Nathuram Thakkar as Non-Executive Non-Independent Director and Vishnu Harjivanbhai Thaker as Company Secretary. Both appointments are effective 31 October 2026.
Chennai Petroleum Corporation Management Change
Chennai Petroleum's Director (Operations) P. Kannan ceased on superannuation, effective 31 October 2026. S. G. Venkatesh takes additional charge from 1 November 2026.
GAMCO Management Change
GAMCO appointed Jayshri Tulsyan as Non-Executive Independent Director for 24 months, effective October 31, 2026. Ayushi Khaitan resigned as Non-Executive Non-Independent Director, citing personal reasons.
Dhampur Bio Organics Management Change
Dhampur Bio Organics' VP Financial Planning and Analysis, Harmeet Singh, resigned, effective October 31, 2026. It is a senior management departure.